Advanced search
Publication Cover
Modern Rheumatology Volume 26, 2016 - Issue 4
Journal homepage
605
Views
15
CrossRef citations to date
0
Altmetric
Letter

Tofacitinib can decrease anti-DNA antibody titers in inactive systemic lupus erythematosus complicated by rheumatoid arthritis

Motohisa YamamotoDivision of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, JapanCorrespondence[email protected]
,
Yoshihiro YokoyamaDivision of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan
,
Yui ShimizuDivision of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan
,
Hidetaka YajimaDivision of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan
,
Nodoka SakuraiDivision of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan;Department of Pediatrics, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan
,
Chisako SuzukiDivision of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan
,
Yasuyoshi NaishiroDivision of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan
&
Hiroki TakahashiDivision of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan
 show all
Pages 633-634 | Received 19 May 2015, Accepted 27 Jun 2015, Published online: 03 Aug 2015

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Kunihiro Yamaoka. (2019) Tofacitinib for the treatment of rheumatoid arthritis: an update. Expert Review of Clinical Immunology 15:6, pages 577-588.
Read now
Abraham M. Korman, Dane Hill, Ali Alikhan & Steven R. Feldman. (2016) Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis. Expert Review of Clinical Pharmacology 9:4, pages 525-539.
Read now
Anna Sophie Klaeschen & Joerg Wenzel. (2016) Upcoming therapeutic targets in cutaneous lupus erythematous. Expert Review of Clinical Pharmacology 9:4, pages 567-578.
Read now

Articles from other publishers (12)

Patricia Richter, Anca Cardoneanu, Alexandra Maria Burlui, Luana Andreea Macovei, Ioana Bratoiu, Oana Nicoleta Buliga-Finis & Elena Rezus. (2022) Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?. International Journal of Molecular Sciences 23:19, pages 11788.
Crossref
Przemysław Kotyla, Olga Gumkowska-Sroka, Bartosz Wnuk & Kacper Kotyla. (2022) Jak Inhibitors for Treatment of Autoimmune Diseases: Lessons from Systemic Sclerosis and Systemic Lupus Erythematosus. Pharmaceuticals 15:8, pages 936.
Crossref
Yu-Lan Chen, Li-Xiong Liu, Qin Huang, Xue-Ying Li, Xiao-Ping Hong & Dong-Zhou Liu. (2021) Case Report: Reversal of Long-Standing Refractory Diffuse Non-Scarring Alopecia Due to Systemic Lupus Erythematosus Following Treatment With Tofacitinib. Frontiers in Immunology 12.
Crossref
Ayida Al Khalili & Jan P. Dutz. (2020) Janus Kinase Inhibition and SLE: Is this a Plausible Treatment Option for SLE?. Current Treatment Options in Rheumatology 6:4, pages 406-417.
Crossref
Hanxiao You, Dong Xu, Jiuliang Zhao, Jing Li, Qian Wang, Xinping Tian, Mengtao Li & Xiaofeng Zeng. (2020) JAK Inhibitors: Prospects in Connective Tissue Diseases. Clinical Reviews in Allergy & Immunology 59:3, pages 334-351.
Crossref
E. L. Nasonov, A. S. Avdeeva & A. M. Lila. (2020) EFFICACY AND SAFETY OF TOFACITINIB FOR IMMUNEMEDIATED INFLAMMATORY RHEUMATIC DISEASES (PART II). Rheumatology Science and Practice 58:2, pages 214-224.
Crossref
Hanxiao You, Guizhi Zhang, Qian Wang, Shangzhu Zhang, Jiuliang Zhao, Xinping Tian, Hongbin Li, Mengtao Li & Xiaofeng Zeng. (2019) Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Annals of the Rheumatic Diseases 78:10, pages 1441-1443.
Crossref
Christophe RICHEZ, Jacques MOREL, Divi CORNEC, Claire DAÏEN, Philippe GOUPILLE, Estibaliz LAZARO, Thierry LEQUERRÉ, Gaëtane NOCTURNE, Victor de LÉDINGHEN, Benoit Le GOFF, Valérie POURCHER, Clément PRATI, Raphaèle SEROR, Anne TOURNADRE, Marie-Elise TRUCHETET, Jean SIBILIA & Thao PHAM. (2019) Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR). Joint Bone Spine 86, pages eS2-eS103.
Crossref
E. L. NasonovA. S. Avdeeva. (2019) IMMUNOINFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TYPE I INTERFERON: NEW EVIDENCE. Rheumatology Science and Practice 57:4, pages 452-461.
Crossref
Raquel de la Varga Martínez, Beatriz Rodríguez-Bayona, Gustavo A. Añez, Fermín Medina Varo, José J. Pérez Venegas, José A. Brieva & Carmen Rodríguez. (2017) Clinical relevance of circulating anti-ENA and anti-dsDNA secreting cells from SLE patients and their dependence on STAT-3 activation. European Journal of Immunology 47:7, pages 1211-1219.
Crossref
William Damsky & Brett A. King. (2017) JAK inhibitors in dermatology: The promise of a new drug class. Journal of the American Academy of Dermatology 76:4, pages 736-744.
Crossref
Èlia Ripoll, Laura de Ramon, Juliana Draibe, Ana Merino, Nuria Bolaños, Montse Goma, Josep M. Cruzado, Josep M. Grinyó & Juan Torras. (2016) JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Research & Therapy 18:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.